Latest news and research on all cancers and treatments, updated several times a week, plus 10,000-item data base of these
... under the therapy special drugs were injected in patient's body to 'wake up' the immune system as a weak system makes treatment of cancer difficult ...
Likewise on Guam, lung cancer accounts for the highest amount of death ... system by blocking the ability of the immune system to fight the cancer."
The physician-scientists at Dana-Farber Cancer Institute in Boston will create ... Other drugs can improve outcomes by amplifying the immune system's ...
But only cancer cells follow the recipe to make the biomarker. ... Ordinarily, a mouse's immune system would attack any injected human cell, ...
Ipilimumab is one of a new class of cancer treatments that target the immune system, and works by homing in on a molecule found on immune cells ...
A 2007 Harvard study published in the Journal of the National Cancer ... good oral health by improving the circulatory system and immune system.
"These biomarkers include genes that track how fast the tumors are growing and how active the immune system is in the tumor," said Kwong.
... who will discuss current advances in bladder cancer immunotherapy. ... to educate and activate a cancer patient's immune system to recognize and ...
Engineered Biomarkers Could ID Cancer Cells
Delivering DNA that results in the production of a tumor cell-specific reporter protein detectable in the blood could be a new method for earlier tumor identification, according to a proof-of-concept study published today
Fighting cancer boxing gloves In order for mesothelioma treatment to be successful, the tumors need to shrink. For that to happen, first the drugs need ...
The orphan drug status was given for the pancreatic cancer indication which is still a huge unmet medical need for many cancer patients. Pancreatic ...
This hydrogel treatment for cancer is capable of isolating pathogenic cells ... In 2012, 37,390 pancreatic cancer patients died out of a total of 43,920 ...
... and the successful launch and further commercial development of the suite of Cxbladder products for detecting and managing bladder cancer.
Shares of Celldex Therapeutics jumped nearly 17% on the news that the US Food and Drug Administration has granted breakthrough therapy ...
An abstract entitled: "Combining active immunotherapy and immune checkpoint inhibitors in prostate cancer" (Abstract #172) is also available online ...
—It's the fifth most common type of cancer in U.S. adults. Now ... Dr. Vose is offering a clinical trial involving a type of immunotherapy called Chimeric ...
Science Daily Cancer News
There are no effective available treatments for sufferers of Glioblastoma multiforme, the most aggressive and devastating form of brain tumor. Now a study may offer hope to the tens of thousands diagnosed with gliomas every year, using a nanomedical treatment first engineered to tackle ovarian cancer tumors.
Clinical trials are underway of anti-androgen drugs against high-androgen triple-negative breast cancers, and new work shows the threshold for benefit from anti-androgen therapies may be much lower than previously thought: even breast cancers with few androgen receptors benefit from anti-androgen therapy.
Researchers have identified the first genetic variation that is associated with increased risk and severity of peripheral neuropathy following treatment with a widely used anti-cancer drug. Investigators also found evidence of how it may be possible to protect young leukemia patients without jeopardizing cures.
A decline in smoking rates may mean that many people who could have benefited from early detection of lung cancer are dying because they don’t qualify for low-dose CT scans, according to a group of researchers.
An analysis of lung cancer incidence and screening found a decline in the proportion of patients with lung cancer meeting high-risk screening criteria, suggesting that an increasing number of patients with lung cancer would not have been candidates for screening, according to a study.
Children with acute lymphoblastic leukemia who had a certain gene variant experienced a higher incidence and severity of peripheral neuropathy after receiving treatment with the cancer drug vincristine, according to a study.
Scientists have identified weak spots in cancer cells that could be targeted and attacked by new precision drugs.
Findings from a small prospective study suggest that androgen receptor V7 (or AR-V7) status does not significantly affect response to taxane chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC). Treatment outcomes were largely similar for the 17 patients with AR-V7-positive prostate cancer and the 20 patients with AR-V7-negative disease included in this analysis.
Men who have had testicular cancer are more likely to develop prostate cancer, although overall risk of developing aggressive disease is low
A case-control study of close to 180,000 men suggests that the incidence of prostate cancer is higher among men with a history of testicular cancer (12.6 percent) than among those without a history of testicular cancer (2.8 percent). Men who have had testicular cancer were also more likely to develop intermediate- or high-risk prostate cancers.
An analysis of data on 945 patients with prostate cancer that is managed with active surveillance shows differences in outcomes depending on whether the patient was low or intermediate risk at diagnosis. Compared to patients with low-risk disease, those with intermediate-risk cancer (PSA >10ng/ml or Gleason score 7 or clinical stage T2b/2c) had a nearly four-fold higher chance of dying from prostate cancer within 15 years.
Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years).
An analysis of data on roughly 87,500 men treated for prostate cancer since 2005 finds a notable increase in higher-risk cases of the disease between 2011 and 2013.
Household net worth is a major and overlooked factor in adherence to hormonal therapy among breast cancer patients and partially explains racial disparities in quality of care. Several studies have shown that disparities in income contribute to disparities in health care between racial and ethnic groups, but no one had specifically analyzed the effect of household net worth on quality of care in breast cancer patients until now.
Powerful drugs known as BRAF-inhibitors have been crucial for melanoma patients, saving lives through their ability to turn off the BRAF protein’s power to spur cancer cell growth. Yet they often work for only a year or less. Scientists know some of the DNA mutations that cause the drug resistance, but scientists have not been able to determine the underlying cause of the resistance in as many as a third of these patients. Now researchers may have found a way to more accurately predict which patients will likely respond to genomic-based follow-up therapies, by looking at unique “protein patterns” in melanoma patients.
Two widely used targeted therapy drugs— approved by the FDA for use in metastatic kidney cancer —are no more effective than a placebo in preventing return of the disease to increase life spans of patients suffering from advanced kidney cancer after surgery, according to new research results.
Tambahkan Komentar